Nobilis Therapeutics is developing proprietary inhalation-based therapeutics using controlled self-administration of inert gases to address unmet medical need in the treatment of psychiatric and neurodegenerative diseases.

By leveraging data on more than 500 patients successfully treated for conditions ranging from panic disorder to autoimmune diseases, Nobilis has coupled its patent pending gas mixtures with a proprietary inhalational device to offer reproducible, standardized, and controlled patient exposure. The Company is currently advancing its technologies into human clinical trials.

Twitter Feed

Nobilis Therapeutics @NobilisTx
New Nobilis Therapeutics Zephyrus device is almost ready https://t.co/J7ICLnUEes
h J R
Nobilis Therapeutics @NobilisTx
NBTX-001 shows promise in treatment of Panic Disorder. Study results published in Journal of Translational Medicine.#panicdisorder#NobilisTx
h J R
Nobilis Therapeutics @NobilisTx
This is huge! Company receives a notice of allowance for a patent covering treatment of psychiatric disorders with noble gases #NobilisTx
h J R
Nobilis Therapeutics @NobilisTx
Nmda receptors critical to social interaction Xenon modulates nmda receptors https://t.co/VJ53Ai2125
h J R